F. Hoffmann-La Roche Ltd: FDA accepts supplemental Biologics

First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase III POLARIX study

Related Keywords

Lugano , Ticino , Switzerland , Japan , United States , America , Gazyvaro Gazyva , Mabthera Rituxan , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Sileia Urech , Loren Kalm , Karsten Kleine , Nathalie Altermatt , Genentech , Lymphoma Study Association , Roche Group , Roche Group Media Relations , Lymphoma Academic Research Organisation , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Hoffmann , Oche , Oaccepts , Supplemental , Iologics , License , Application , Polivy , Combination , People , Reviously , Untreated , Diffuse , Barge , Fell , Lymphoma ,